232
Views
7
CrossRef citations to date
0
Altmetric
Research Articles

Design, synthesis, anti-acetylcholinesterase evaluation and molecular modelling studies of novel coumarin-chalcone hybrids

ORCID Icon, ORCID Icon, , ORCID Icon, , ORCID Icon, , , & ORCID Icon show all
Pages 11450-11462 | Received 01 Aug 2022, Accepted 19 Dec 2022, Published online: 02 Jan 2023
 

Abstract

The major enzyme responsible for the hydrolytic breakdown of the neurotransmitter acetylcholine (ACh) is acetylcholinesterase (AChE). Acetylcholinesterase inhibitors (AChEIs) are the most prescribed class of medications for the treatment of Alzheimer’s disease (AD) and dementia. The limitations of available therapy, like side effects, drug tolerance, and inefficacy in halting disease progression, drive the need for better, more efficacious, and safer drugs. In this study, a series of fourteen novel chalcone-coumarin derivatives (8a-n) were designed, synthesized and characterized by spectral techniques like FT-IR, NMR, and HR-MS. Subsequently, the synthesized compounds were tested for their ability to inhibit acetylcholinesterase (AChE) activity by Ellman’s method. All tested compounds showed AChE inhibition with IC50 value ranging from 0.201 ± 0.008 to 1.047 ± 0.043 μM. Hybrid 8d having chloro substitution on ring-B of the chalcone scaffold showed relatively better potency, with IC50 value of 0.201 ± 0.008 μM compared to other members of the series. The reference drug, galantamine, exhibited an IC50 at 1.142 ± 0.027 μM. Computational studies revealed that designed compounds bind to the peripheral anionic site (PAS), the catalytic active site (CAS), and the mid-gorge site of AChE. Putative binding modes, ligand-enzyme interactions, and stability of the best active compound are studied using molecular docking, followed by molecular dynamics (MD) simulations. The cytotoxicity of the synthesised derivatives was determined using the MTT test at three concentrations (100 g/mL, 500 g/mL, and 1 mg/mL). None of the chemicals had a significant effect on the body at the highest dose of 1 mg/mL.

Communicated by Ramaswamy H. Sarma

Author contributions

Joazaizulfazli Jamalis, Sankaranarayanan Murugesan and Subhash Chander-supervision, investigation and critical review; Basundhara Das, Subhrajit Biswas, Sonam Shakya and Mohammad Rizki Fadhil Pratama-methodology, software’s, investigation, formal analysis, data curation, interpretation of data and revision; Faiq H.S. Hussain, Shajarahtunnur Jamil and Aso Hameed Hasan, design of study, methodology, investigation, and original draft. All authors critically reviewed and approved the manuscript before submission.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

The authors would like to express their gratitude to Universiti Teknologi Malaysia (UTM) and the Ministry of Higher Education (MOHE) Malaysia for sponsoring this research through the Fundamental Research Grant Scheme (FRGS/1/2019/STG01/UTM/02/7).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.